Pancreatic Exocrine Tumors

More than 95% of pancreatic cancers are classified as exocrine tumors.  These tumors start in the exocrine cells of the pancreas.  The following table describes the most common pancreatic exocrine tumors.

Adenocarcinoma Adenocarcinoma is the most common type of pancreatic cancer.  It accounts for about 90% of all pancreatic cancers.  It begins in the cells lining the pancreatic duct.
Acinar Cell Carcinoma Acinar cell carcinoma is a very rare form of pancreatic cancer. Some tumors may cause excessive production of pancreatic lipase, the enzyme secreted to digest fats.  Pancreatic lipase levels can be measured in the blood.
Intraductal Papillary-Mucinous Neoplasm (IPMN) An IPMN is a cystic tumor that grows from the main pancreatic duct or from side branches of the duct.  The tumor may appear as a finger-like (papillary) projection into the duct.  An IPMN may be benign at the time of diagnosis.  However, it has a risk of progressing to malignancy.  This risk is high when the IPMN originates in the main pancreatic duct.  An IPMN may therefore be a precursor for adenocarcinoma.
Mucinous Cystadenocarcinoma Mucinous cystadenocarcinoma is a rare, malignant, cystic tumor.  The cyst is filled with a thick fluid called mucin.  It is similar to an IPMN but occurs in just one area of the pancreas, more commonly in the tail of the pancreas. These tumors are mostly seen in women.

There are other rare types of exocrine pancreatic tumors not discussed in this table.  For information about other types of exocrine pancreatic tumors, contact our Patient and Liaison Services (PALS) program at

The information and services provided by the Pancreatic Cancer Action Network, Inc. are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. If you are ill, or suspect that you are ill, see a doctor immediately! The Pancreatic Cancer Action Network does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site. In addition, please note that any personal information you provide to the Pancreatic Cancer Action Network’s associates during telephone and/or email consultations may be stored in a secure database to assist the Pancreatic Cancer Action Network, Inc. in providing you with the best service possible. Portions of the constituent data stored in this database may be used to inform future programs and services of the Pancreatic Cancer Action Network, Inc., and may be provided in aggregate form to third parties to guide future pancreatic cancer research and treatment efforts. The Pancreatic Cancer Action Network, Inc. will not provide personal identifying information (such as your name or contact information) to third parties without your advanced written consent. 131217